Bio-equivalence and generic drugs. Studies of bio-equivalence. II. Special situations. Reflections on problems which may arise with drugs habitually used in neurology;Bioequivalencia y genericos. Los estudios de bioequivalencia. II. Situaciones especiales. Reflexiones acerca de problemas que pueden aparecer con farmacos utilizados habitualmente en neurologia

Revista de Neurologia

Volumn 30, Issue 2, 2000, Pages 146-154

  Zapater, P ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Average bio equivalence; Controlled release formulations; Enantiomers; Excipients; Individual bio equivalence; Non linear pharmacokinetics; Therapeutic bio equivalence

Indexed keywords

CARBAMAZEPINE; EXCIPIENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GENERIC DRUG; NIFEDIPINE; VERAPAMIL;

ARTICLE; BIOEQUIVALENCE; CONTROLLED RELEASE FORMULATION; DRUG USE; ENANTIOMER; NEUROLOGY; PHARMACOKINETICS; STEREOISOMERISM; HUMAN; REVIEW;

CALCIUM CHANNEL BLOCKERS; CARBAMAZEPINE; DILTIAZEM; DRUGS, GENERIC; HUMANS; NEUROLOGY; NIFEDIPINE; STEREOISOMERISM; THERAPEUTIC EQUIVALENCY; VERAPAMIL;

EID: 0034672990     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3002.99596     Document Type: Article

References (24)

1. Steinijans VW, Hauschke D, Jonkman JHG. Controversies in bioequivalence studies. Clin Pharmacokinet 1992; 22: 247-53.
2. Patnaik RN, Lesko LJ, Chen ML, Williams RL, FDA individual bioequivalence working group. Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. Clin Pharmacokinet 1997; 33: 1-6.
3. Gilman JF, Álvarez LA, Duchowry M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993; 43: 2696-7.
4. Koch G, Allen JF. Untoward effects of generic carbamazepine therapy. Arch Neurol 1987; 44: 578-9.
5. Sachdeo RC, Belendiuk G. Generic versus branded carbamazepine. Lancet 1987; 1: 1432.
6. Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992; 26: 775-7.
7. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Rida AR. Therapeutic bioequivalence study of brand name versus generic carbamazepine. Neurology 1992; 42: 1147-52.
8. Hartley R, Aleksandrowicz J, Ng PC, McLain B, Browner CJ, Farsythe WI. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? Br J Clin Pract 1990; 44: 270-3.
9. Yacobi A, Zlotnick S, Colaizzi JL, Moros D, Masson E, Abolfathi Z, et al. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine. Clin Pharmacol Ther 1999; 65: 389-94.
10. Van Rossum JM, van Lingen G, Burgess JPT. Dose dependent kinetics. Pharmacol Ther 1983; 21: 77-100.
11. Browne TR, Szabo GK, McEntegart C. Bioavailability studies of drugs with nonlinear pharmacokinetics. II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique. J Clin Pharmacol 1993; 33: 89-94.
12. Schall R, Müller FR, Müller O, Luus HE. Bioequivalence of controlled-release calcium antagonists. Clin Pharmacokinet 1997; 32: 75-89.
13. Psaty BM, Heckbert S. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.
14. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary hearth disease. Circulation 1995; 92: 1326-31.
15. Dougall HT, McLayn J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996; 15: 91-106.
16. Wagenknecht LE, Furberg CD, Hammon JW, Legault C, Troost BT. Surgical bleeding: unexpected effects of a calcium antagonist. Br Med J 1995; 310: 776-7.
17. Argenti D, Huang MY, Heald D. Comparative pharmacokinetics and bioavailability of Dilacor XR and Cardizem CD in healthy volunteers. Am J Ther 1995; 2: 20-30.
18. Guimont S, Landriault H, Klischer K, Grace M, Lambert C, Caille G, et al. Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers. Biopharm Drug Dispos 1993; 14: 767-78.
19. Lippert CL, Arumugham T, Bhargava VO, Eller M, Weir SJ. The relative bioavailability of two marketed controlled-release diltiazem dosage forms at steady-state in healthy volunteers. Biopharm Drug Dispos 1996; 17: 43-53.
20. Tróger U, Martens J, Meyer FP, Hoffmann A, Terhaag B. Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses. Arzneimittelforschung 1995; 45: 1266-70.
21. Seth P, Seth PL. An in-vivo bioequivalence study of a new nifedipine extended release dosage form. 'Opticaps'. Drug Dev Industrial Pharm 1994; 20: 1605-12.
22. Meyer FP, Banditt P. Investigation into the bioequivalence of two nifedipine controlled-release formulations after single application and in steady-state. Arzneimittelforschung 1993; 43: 646-50.
23. Meyer FP, Banditt P. Zum Nachweis der bioäquivalenz von zwei Nifedipin-Formulierungen. Z Clin Med 1991; 46: 1141-4.
24. Schall R, Müller FO, Hundt HKL, Duursema L, Groenewoud G, van-Dyk M, et ai. Relative bioavailability of four controlled-release nifedipine products. Biopharm Drug Dispos 1994; 15: 493-503.